Cloud-Based Collaboration: The Future of Pharma

Home » Cloud-Based Collaboration: The Future of Pharma

Cloud-Based Collaboration: The Future of Pharma

750x195 interviewExostar, an innovative information technology company offering cloud-based solutions that enable secure, cost-effective business-to-business collaboration, was formed in 2000. Daniel Pfeifle, Exostar’s Vice President of Sales and Marketing, explains: “We created an aerospace/defence hub for collaborative supply chain processes and, during a period of 6–7 years, and a phase of acquisition, we developed an identity hub for the aerospace industry, which had a shared collaborative environment that Exostar provided in the cloud, where large, multinational companies could access our applications and/or so-called customer applications.”

“By 2009/2010, we began to explore the life science space. Interestingly,” he notes, “at the time, the life science sector was about 5–7 years behind the aerospace/defence community. The companies were working in isolation, within their own four walls, and processes such as drug development, resourcing, IT and so forth, were all kept completely internal. With time, though, some of the bigger players realised that, to reduce costs, in such a competitive — and rapidly expanding global — market, they had to improve their overall efficiency to achieve faster times to market. And, to do that, they needed to collaborate with partners and service providers on a worldwide basis.”

Now, with more than a decade of experience developing, integrating and hosting Identity & Access Management (IAM), data protection and information collaboration solutions, our comprehensive cloud-based Software-as-a-Service (SaaS) model provides organizations with a secure architecture so they can conduct business with all of their colleagues, partners, suppliers and customers more efficiently and effectively. Organizations connect once, eliminating redundant infrastructure while reducing onboarding and provisioning times from weeks or months to days.

Pharmaceutical companies spend upwards of a decade and a billion dollars to bring new drugs and therapies from concept to market. These astronomical investments have manufacturers and their partners considering all options to reduce the cost and schedule of the drug R&D process. Searching for answers is difficult, particularly if organizations rely on outmoded technology.

Currently, Exostar’s life science and healthcare community includes nearly 15,000 users and 700 organizations, as well as seven federated organizations and more than 20 federated applications. Global market leaders such as Merck, AstraZeneca and MedImmune, along with their contract research organization, academic, laboratory and investigator partners, are reaping the time, cost, and security advantages of the Life Sciences Identity Hub.

Exostar’s Life Sciences Identity Hub is the scalable, proven solution where asset owners maintain control over access to their applications, which the Identity Hub enforces via Exostar’s Secure Access Manager (SAM). With heightened security for sensitive information and intellectual property, organizations can collaborate with confidence. Individuals benefit from a single sign-on user experience, which reduces risk and vulnerability while promoting productivity with seamless access to multiple next-generation life science technology solutions.

“What we do,” says Daniel, “is power secure business-to-business information sharing, collaboration and business process integration throughout the entire value chain.” Exostar supports the complex trading needs of many of the world’s largest companies in aerospace and defence, life sciences and other industries. “Our combination of technical innovation, customer intimacy and a commitment to maintaining security at all levels has made Exostar the preferred solution for companies who are highly reliant on multi-organization information sharing, but also have advanced requirements for security and information oversight. Our cloud-based identity assurance products and business applications reduce risk, improve agility and strengthen trading partner relationships and profitability for more than 100,000 companies in 150 countries worldwide,” he adds.

Looking to the future, Daniel comments: “What happens next is always a good question, because the answer changes from day to day. Change management, however, is a key driver, and affects how organizations work with their partners and suppliers. What you’re going to see is more outsourcing of key applications and externalization to third parties, into the cloud, for example. One particular area of interest, where we’re seeing a lot of growth, is academic/institution involvement with life science companies, who are leveraging that knowledge base to achieve a competitive edge.”

He concludes: “More rapid access to information at faster speeds will generate a culture of more imaginative and collaborative product and process development, reduced costs and, of course, faster times to market. Exostar has become the preferred choice for providing secure cloud-based access to scientific solutions and we look forward to continuing to create and deliver the innovative, impactful tools that help our customers utilize and protect their intellectual property, streamline the partner lifecycle, implement new engagements and expedite all phases of their supply chain.”